JOSEPH M. LENEHAN, MD

Plain English
This study looked at how a specific type of radiation therapy, called stereotactic ablative body radiotherapy (SABR), affects the blood flow in pancreatic tumors, which could lead to better delivery of cancer treatments. Researchers found that after the first treatment, blood flow increased significantly in two of the patients, and even after all treatments were finished, blood flow and other measures related to tumor activity improved compared to the initial scans. This matters because enhancing blood flow may help make standard cancer therapies more effective. Who this helps: This helps patients with resectable or borderline-resectable pancreatic cancer.

Plain English
This study looked at how a specific type of genetic testing, called genomic profiling, helps doctors better manage advanced solid tumors in 554 patients. The results showed that 79% of patients had genetic changes that were important for treatment decisions, and nearly 28% were eligible for new therapies because of these findings. This matters because it helps improve patient care, allowing for more personalized treatments and better outcomes. Who this helps: This benefits cancer patients seeking more effective treatment options tailored to their specific genetic profiles.

Plain English
This study looked at how fecal microbiota transplantation (FMT) combined with immunotherapy affects patients with two types of cancer: non-small cell lung cancer (NSCLC) and melanoma. Researchers found that 80% of NSCLC patients responded well to this treatment, and 75% of melanoma patients saw positive results. This is important because it shows that FMT can enhance the effectiveness of cancer treatments, particularly for patients who usually don’t respond well to immunotherapy. Who this helps: This helps cancer patients who are not responding to standard immunotherapy treatments.

Plain English
This study looked at the challenges women in rural Australia face when trying to access sexual and reproductive health services. Researchers reviewed 50 studies and found that many women struggle due to issues like limited service availability (58% of studies focused on primary care), negative attitudes from healthcare providers, and high costs. Addressing these barriers is crucial because it can lead to better health outcomes and reduce inequalities for women in these areas. Who this helps: This helps women living in rural Australia.

Plain English
This study looked at how using corticosteroids before starting immunotherapy affects survival in patients with advanced melanoma. It included 166 patients, with 25 of them taking corticosteroids. The findings showed that while taking low doses (10-49 mg) of steroids didn’t impact survival, patients on higher doses (50 mg or more) had significantly shorter survival rates, roughly twice as likely to face poor outcomes compared to those on lower doses. Who this helps: This helps doctors better understand the risks of corticosteroid use in melanoma treatment.

Plain English
This study looked at how testing a specific gene (DPYD) before chemotherapy can help manage side effects from a type of cancer drug known as fluoropyrimidines. Out of 1,394 patients, 23% of those with gene variants and 31% without experienced severe side effects, showing no significant difference between the two groups. This is important because it suggests that using gene testing for dosing can safely reduce side effects in North America, potentially improving treatment outcomes for patients. Who this helps: Patients undergoing chemotherapy.

Plain English
This study looked at breast cancer patients taking medications called aromatase inhibitors (AIs) and how they sometimes experience joint pain (arthralgia). Out of 196 patients, over 50% reported symptoms of joint pain during treatment, and specific genetic factors (four genetic markers) along with higher body weight were linked to an increased likelihood of developing this pain. Additionally, patients on the drug letrozole were more likely to experience joint pain and stop their treatment compared to those on anastrozole, indicating the need for tailored approaches to manage side effects. Who this helps: Patients receiving breast cancer treatment with aromatase inhibitors.

Plain English
This study explored how the genetic variation of a liver enzyme (CYP2A6) affects the levels of the breast cancer drug letrozole in patients and whether these levels relate to joint pain caused by the drug. They found that more than half of the 126 women experienced increased joint pain after starting treatment, and those with certain genetic variations had higher letrozole levels. However, the study showed that neither letrozole levels nor CYP2A6 genetics were linked to worsening pain. Who this helps: This helps breast cancer patients and their doctors better understand the factors affecting treatment side effects.

Plain English
This study looked at how a breastfeeding app, called Breastfeeding Solutions, was received by new mothers in rural Australia. The results showed that 93.5% of users liked the app and found it helpful, and 79% of participants were still breastfeeding after six months, compared to about 50% in the general local population. This matters because it highlights how effective tools like apps can support rural mothers in breastfeeding, even though we can’t say the app directly caused the higher breastfeeding rates. Who this helps: New mothers in rural areas.

Plain English
This study looked at how certain genes affect the way patients with advanced colorectal cancer respond to a chemotherapy drug called irinotecan. Researchers found that a specific genetic variation (SLCO1B1 521C) was linked to higher levels of the drug's active form, increasing the risk of toxic side effects. Patients with another genetic marker (ABCC2-24C/T) were less likely to experience severe side effects like low white blood cell counts and diarrhea, while those with higher levels of a protein (OATP1B3) in their tumors had shorter periods without disease progression. Who this helps: This research benefits colorectal cancer patients by providing insights for more personalized chemotherapy treatment.

Plain English
This study looked at three women with advanced endometrial cancer who have specific genetic mutations called BRCA1 mutations. Despite having a severe form of cancer (stage IVB), these women have lived for between 3.3 and 14.6 years after their diagnosis and have shown no signs of the cancer coming back. This finding suggests that having BRCA mutations might be linked to better survival outcomes for women with this type of cancer. Who this helps: This information benefits patients with BRCA mutations and their doctors by providing insights into their cancer prognosis.

Plain English
This study focused on understanding how certain drugs that block a protein called CK2 work and how specific they are in their effects. Researchers tested three inhibitors—TBB, TBBz, and DMAT—finding that they primarily target CK2 but also have unexpected interactions with other proteins. Notably, TBBz and DMAT led to cell death through mechanisms beyond just targeting CK2, highlighting the need for improved drugs that are more precise. Who this helps: This benefits cancer patients by supporting the development of safer and more effective treatments.